Recommended dosage modifications for adverse reactions in patients treated with TEVIMBRA¹

*Based on the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.

^†Resume in patients with complete or partial resolution (grades 0 to 1) after corticosteroid taper. Permanently discontinue if no complete or partial resolution within 12 weeks of initiating steroids or inability to reduce prednisone to 10 mg per day or less (or equivalent) within 12 weeks of initiating steroids.

^‡If AST and ALT are less than or equal to ULN at baseline, withhold or permanently discontinue TEVIMBRA based on recommendations for hepatitis with no liver involvement.

^§Resume infusion if resolved or decreased to Grade 1, and slow rate of infusion by 50% of the previous rate.